As Amgen’s flagship PCSK9 cholesterol drug Repatha enjoys a bit of a renaissance on the back of impressive cardiovascular risk reduction data last year, the company is confident it can keep that ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Repatha is the Only PCSK9 Inhibitor Proven to Significantly Reduce Risk of First Heart Attack and Stroke in Phase 3 Clinical Trial, Setting a New Benchmark in Cardiovascular Risk Reduction ...

Repatha was first approved in 2015 and has since been used by more than 10 million patients globally. 10 In August 2025, the U.S. Food and Drug Administration broadened the approved use of Repatha to ...

You've been managing your cholesterol the best you can, but during your last check-up, you received the same message: Your “bad” LDL cholesterol was still too high. So your doctor recommended Repatha, ...

Repatha lowers LDL cholesterol more than statins and may cause fewer muscle aches, higher blood sugar, and elevated liver enzymes. Doctors say it is an injectable prescription medicine given under the ...

The company’s new A.I. image generator has a surprising twist: It allows people to use images from public Instagram accounts. By Eli Tan Reporting from Seattle When Meta unveiled an artificial ...

Please provide your email address to receive an email when new articles are posted on . In patients with atherosclerosis or diabetes who had PCI but no prior heart attack or stroke, evolocumab reduced ...

Using 2024 gross, pre-rebate spending figures for a like-for-like comparison across Medicare, Medicaid, and Denmark, we found that Medicare Part D is by far Repatha’s largest single-payer exposure, at ...

Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its newer products will offset the loss of revenue from patent expirations and ...